Notice of Results

RNS Number : 1285D

Shield Therapeutics PLC

29 January 2018

 

Shield Therapeutics plc

("Shield" or the "Group")

Notice of Results

London, UK, 29 January 2018: Shield Therapeutics plc (LSE:STX), a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs, with an initial focus on addressing anaemia associated with renal and gastrointestinal disorders, announces it will report its results for the year ended 31 December 2017 on Wednesday, 28 February 2018.

Carl Sterritt, Chief Executive Officer and Karl Keegan, Chief Financial Officer, will host a presentation and conference call for analysts at 9.30 a.m. GMT on the morning of the results in the Guildhall Room at 85 Gresham Street, London EC2V 7NQ.

-Ends-

For further information please contact:

Shield Therapeutics plc	[phone]
Karl Keegan, Chief Financial Officer Fleur Wood, Director, Investor Relations
Nominated Adviser and Joint Broker	[phone]
Liberum Capital Limited
Christopher Britton/Steve Pearce
Joint Broker	+ 44 (0)20 7418 8900
Peel Hunt LLP
James Steel/Christopher Golden
Financial PR Adviser	[phone]
Consilium Strategic Communications Mary-Jane Elliott/Matthew Neal	[e-mail]
US Investor Relations	[phone]
Lazar Partners
Fern Lazar/David Carey

About Shield Therapeutics plc

Shield is a commercial stage, pharmaceutical company delivering innovative specialty pharmaceuticals to address patients' unmet medical needs.  Our clear purpose is to help our patients become people again, by enabling them to enjoy the things that make the difference in their everyday lives.  The Group has a marketed product, Feraccru®, for the treatment of IDA in adult patients with IBD which has exclusive IP rights until the mid-2030's. For more information please visit www.shieldtherapeutics.com. 

 

END

 

 

NORDBGDBGGDBGII